AIM submits Pre-IND application to study Ampligen for Covid-19

This trial will see the subjects being randomised into a 1:1 ratio to get either twice weekly infusions of Ampligen or placebo for a period of twelve weeks. Credit: Miguel Á. Padriñán from Pixabay